|
Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of:
Novel blood-based diagnostics for cancer and chronic diseases
Through the use of our innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with our most advanced program in the area of lung cancer currently under development.
Monoclonal Antibody Microarrays
BSI is developing a line of innovative antibody microarrays for the profiling of native proteins in blood in partnership with microarray and diagnostics companies. The antibody microarrays will facilitate the discovery of novel biomarkers in the life sciences, pharmaceutical and health science sectors.
|
|
|
Location
The headquarters of BSI is at Genopole in the Paris area in France. BSI operates research laboratories in Evry and at its subsidiary, BSI Kft in Debrecen at the University of Debrecen in Hungary.
|
top of page 
contact us
home .
contact us .
terms of use .
sitemap .
